Get informed when a big investor buys or sells
+ Follow-160.22%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Hoth Therapeutics (HOTH) currently reports a ROE of -160.22%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Hoth Therapeutics's ROE history and peer comparisons.
Hoth Therapeutics's ROE of -160.22% is lower than the Healthcare sector average of 13.1%. That is roughly 1322.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Hoth Therapeutics's current -160.22% should be judged against Healthcare norms (sector average: 13.1%) and against HOTH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -160.22%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Hoth Therapeutics, and consider following HOTH for alerts when major investors trade the stock.
Hoth Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -160.22% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HOTH with unrelated industries.